Canaccord analyst William Plovanic raised the firm’s price target on Edwards Lifesciences (EW) to $81 from $75 and keeps a Hold rating on the shares. The firm said while the revenue and TAVR beat made for agood headline, the details leave their thesis unchanged. The revenue beat was mostly driven by TAVR, which they believe was due to OUS contributions, including taking share from Bsoton Scientific (BSX); who recently left the market, and Japan returning to growth.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EW:
- Edwards Lifesciences: Strong Financial Performance and Strategic Advancements Drive Buy Rating
- Edwards Lifesciences price target raised to $90 from $83 at Piper Sandler
- Edwards Lifesciences Announces Leadership Change in TAVR Division
- Strong Growth Potential for Edwards Lifesciences: Buy Rating Affirmed by Analyst Brandon Vazquez
- Edwards Lifesciences Reports Strong Q2 Growth